Create an Account
Welcome & Mission Statement
User Technical Support
Accreditation Legend
System Requirements
13th Orange County Symposium for Cardiovascular Disease Prevention
1-day conference on CVD Prevention
Activity Details
Activity Name: 13th Orange County Symposium for Cardiovascular Disease Prevention
Description: 1-day conference on CVD Prevention
Needs Assessment: The Need to Know
Coronary Heart Disease (CHD) is the leading cause of death in the United States and accounts for about 1 in 6 deaths annually. It has been estimated that nearly one-half of all middle-aged men and one-third of all middle-aged women in the United States will develop some index of CHD. Since 1975, CVD mortality has declined by 24 to 28 percent overall, among men and women, as well as blacks and whites, although men and blacks continue to experience far higher mortality rates at earlier ages than their female and white counterparts, respectively. Since 1990, however, the rate of decline in CVD mortality has slowed.
It has been estimated that half of the decline is due to earlier diagnosis and more aggressive treatment, particularly with adjuvant drug therapies. The remaining half of the decline in CVD mortality is attributable to favorable changes in risk factors, such as the decline in cigarette smoking and the aggressive management of lipids and blood pressure. Contemporary studies now suggest that behavior change and multifactorial risk factor modifications especially smoking cessation and more intensive measures to control hyperlipidemia with diet, drugs, and exercise may slow, halt, or even reverse the progression of atherosclerotic CHD.
Health care providers require ongoing training and education in the field of cardiology, including updates on diagnostic and treatment strategies that assess the risk of coronary artery disease (CAD), peripheral artery disease, congestive heart failure, valvular heart disease, arrhythmias and preventive cardiology. It's imperative that providers stay abreast of new and emerging approaches and understand best practices needed to improve patient outcomes and reduce morbidity and mortality related to CVD.
Course Objectives: Objectives:
* Discuss and translate current national and international guidelines and recommendations on the diagnosis, management and treatment of dyslipidemia, and non-lipid risks, including diabetes, hypertension and obesity
* Differentiate the lipid and lipoproteins that contribute to atherosclerotic cardiovascular (ASCVD) risk and residual risk, including atherogenic cholesterol, lipoprotein(a), and optional measures of atherogenic cholesterol particles for at-risk individuals
* Detail the mechanism of action, efficacy and latest clinical trial evidence for the PCSK9 inhibitors, as well as the appropriate use of these therapies
* Differentiate the role of white coat vs. masked hypertension in cardiovascular risk
Location Information
Meeting Location: DoubleTree Hotel
Location City: Orange
Location State: CA
Location Country: US
Activity Information
Start Date: 10/30/2021
End Date: 10/30/2021
Credit Information
Credit Amount: 7
Credit Unit: Credits
Accreditation: ACCME - Accreditation Council for Continuing Medical Education > AMA PRA Category 1 Credit
Activity Learning Format: Live Activity
Sponsor Name: UC Irvine School of Medicine
Sponsor Address: 836 Health Sciences Rd.
Sponsor City: Irvine
Sponsor State: CA
Sponsor Postal Code: 92697
Sponsor Country: US
Sponsor Phone: 949.824.2394
Sponsor Email:
Contact Information
Contact Name: Lesley Anderson
Contact Address: 333 City Blvd. West, Ste. 400
Contact City: Orange
Contact State: CA
Contact Postal Code: 92868
Contact Country: US
Contact Phone: 714-456-5397
Contact Email:

Type:     Live Activity
18 Registered Users